TAKEDA PHARMACEUTICAL CO LTD

Q3 2025 13F Holdings

  • Location
    tokyo, M0
  • Num holdings

    8

  • Value ($000)

    $16,369

  • Date Filed
    11/13/2025
  • Form type
    13F-HR
  • CIK
    0001395064
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
OVID
OVID

Ovid Therapeutics, Inc.

COM
690469101
$9.79 M
60 %

7,531,996

EQ
EQ

Equillium, Inc.

COM
29446K106
$2.61 M
16 %

1,824,977

XLO
XLO

Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)

COM
98422T100
$1.24 M
8 %

1,475,121

STTK
STTK

Shattuck Labs, Inc.

COM
82024L103
$1.23 M
8 %

515,619

LYEL
LYEL

Lyell Immunopharma, Inc.

COM
55083R104
$891.37 K
5 %

54,887

AMWL
AMWL

American Well Corporation

COM
03044L204
$478.06 K
3 %

77,733

RANI
RANI

Rani Therapeutics Holdings, Inc.

COM
753018100
$101.55 K
1 %

203,190

FLB
FLB

Standard Biotools, Inc.

COM
34385P108
$21.47 K
0 %

16,515

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 8 of 8